776 abstracts found.



Results filter

The assessment and classification of depression in advanced cancer

Year:

Session type:

Alasdair G Rooney1
1Edinburgh Centre for Neuro-oncology, Western General Hospital, Edinburgh, UK

Using GEMM and PDX models of pancreatic cancer to identify new therapeutic opportunities in PDAC

Year:

Session type:

Owen Sansom1
1Cancer Research UK Beatson Institute, Glasgow, UK

Advances in the treatment of depression in advanced cancer

Year:

Session type:

Gary Rodin1,2
1Princess Margaret Cancer Centre, Toronto, Canada, 2University of Toronto, Toronto, Canada

Cervical cancer – problem solved?

Year:

Session type:

Peter Sasieni1
1Wolfson Institute of Preventive Medicine, Queen Mary University, London, London, UK

Humanising mouse models of cancer: how relevant are current models?

Year:

Session type:

Owen Sansom1
1Cancer Research UK Beatson Institute, Glasgow, UK

The biology and clinical exploitation of BRAF and RAS signalling in cancer

Year:

Session type:

Richard Marais1
1The Cancer Reserch UK Manchester Institute, Manchester, UK

A pre-clinical approach to the development of targeted therapeutics for paediatric cancers

Year:

Session type:

Louis Chesler1
1The Institute of Cancer Research, London, UK

Chromosomal instability and hopeful monsters: A driving force for cancer heterogeneity and evolution

Year:

Session type:

Charles Swanton1
1Cancer Research UK London Research Institute and University College London Cancer Institute, London, UK

The application of mouse models humanised for pathways controlling drug metabolism and disposition in anticancer drug development

Year:

Session type:

C Roland Wolf1
1University of Dundee, Dundee, UK

Inflammation and cancer: Reprogramming the immune microenvironment as an anti-cancer therapeutic strategy

Year:

Session type:

Lisa M Coussens1
1Knight Cancer Institute, Oregon Health & Sciences University, Portland, USA

Sarcoma – state of the art and science

Year:

Session type:

Penella Woll1
1Weston Park Hospital, Sheffield, UK

Cancer Research UK Lifetime Achievement Award winner: Polygenic susceptibility: What might it tell us?

Year:

Session type:

Bruce Ponder1
1Cancer Research UK Cambridge Institute, Cambridge, UK

GIST molecular advances: Maximising response to targeted therapies

Year:

Session type:

Jonathan A Fletcher1
1Brigham and Women's Hospital, Boston, USA

Defective DNA strand break repair, genome instability and cancer

Year:

Session type:

Stephen C West1
1Cancer Research UK London Research Institute, South Mimms, UK

Developments in understanding the biology of bone sarcomas

Year:

Session type:

Bass Hassan1
1University of Oxford, Oxford, UK

The application of translational science in non-small cell lung cancer (NSCLC): Successes, failures and pitfalls

Year:

Session type:

Frances A Shepherd1
1Princess Margaret Hospital and University of Toronto, Toronto, Canada

Supporting family carers: International evidence

Year:

Session type:

Sheila Payne1
1Lancaster University, Lancaster, UK

Improving value in cancer care: The case for palliative medicine

Year:

Session type:

R Sean Morrison1
1Hertzberg Palliative Care Institute, National Palliative Care Research Center, and Mount Sinai Medical Center, New York, USA

CCLG prizewinner: RNA helicase A is essential for 1p36 gene KIF1Bb tumour suppression in neuroblastomas

Year:

Session type:

Zhi Xiong Chen1
1Ludwig Institute for Cancer Research, Solna, Sweden and National University of Singapore, Singapore, Singapore

Linking cancer exomes to cancer immunotherapy

Year:

Session type:

Ton Schumacher1
1Netherlands Cancer Institute, Amsterdam, The Netherlands

T cell-based immunotherapy approaches for neuroblastoma

Year:

Session type:

Karin Straathof1
1University College London Institute of Child Health and Great Ormond Street Hospital, London, UK, London, UK

Chimeric antigen receptor modified T cells: Does receptor design and cell product composition matter?

Year:

Session type:

Stanley Riddell1,2
1Fred Hutchinson Cancer Research Center, 2University of Washington, Seattle, USA

Haploidentical transplantation as a platform for post-transplant immune therapy in childhood leukaemia

Year:

Session type:

Rupert Handgretinger1
1Children’s University Hospital, Tübingen, Germany

The FAP+ stromal cell establishes dominant immune suppression in an autochthonous model of pancreatic ductal adenocarcinoma

Year:

Session type:

Douglas Fearon1
1University of Cambridge, Cambridge, UK

Natural killer T (NKT) cells as a novel platform for cancer immunotherapy with chimeric antigen receptors

Year:

Session type:

Leonid S Metelitsa1
1Baylor College of Medicine, Houston, USA

Intravital microscopy of cancer invasion, plasticity and integrin function: Targeting cancer resistance

Year:

Session type:

Peter Friedl1,2
1Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 2The University of Texas, MD Anderson Cancer Center, Houston, USA

Refractory breathlessness: Mechanisms and management

Year:

Session type:

Miriam Johnson1
1Hull York Medical School, York, UK

Cell migration in tumours

Year:

Session type:

Erik Sahai1,2
1Cancer Research UK, London, UK, 2London Research Institute, London, UK

Refractory breathlessness: Mechanisms and management

Year:

Session type:

David Currow1
1Flinders University, Adelaide, Australia

Plasticity and physical mechanisms of cell migration in confinement

Year:

Session type:

Ewa Paluch1
1University College London, London, UK

From biology to therapy: a translational approach to breathlessness

Year:

Session type:

Richella Ryan1,2
1University of Cambridge, Cambridge, UK, 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

More than a clinical sign or symptom: The experience of breathlessness in advanced illness

Year:

Session type:

Marjolein Gysels1,2
1Cicely Saunders Institute, King's College London, London, UK, 2Centre for Social Science and Global Health, University of Amsterdam, Amsterdam, The Netherlands

The ‘end game’ for tobacco control in the UK: Key priorities for science and policy to reduce smoking

Year:

Session type:

Linda Bauld1
1University of Stirling, Stirling, UK

Challenges in realising the end game: Dealing with the tobacco industry

Year:

Session type:

Anna B Gilmore1
1University of Bath, Bath, UK

The international context for moving toward the ‘end game’ for tobacco control in the United Kingdom

Year:

Session type:

Geoffrey T Fong1,2
1University of Waterloo, Waterloo, Canada, 2Ontario Institute for Cancer Research, Toronto, Canada

Mitochondrial dysfunction and autophagy in tumour progression and metastasis

Year:

Session type:

Kay Macleod1
1The University of Chicago, Chicago, USA

Smoking prevention: What we need to do

Year:

Session type:

Amanda Amos1
1University of Edinburgh, Edinburgh, UK

DNA damage: An inherent flaw of apoptosis-mediated tumour suppression?

Year:

Session type:

Stephen Tait1
1The Beatson Institute for Cancer Research and University of Glasgow, Glasgow, UK

The importance of knowing which way is up – the role of polarity in tumour suppression

Year:

Session type:

Buzz Baum1
1University College London, London, UK

Translational metabolic treatments for breast cancer

Year:

Session type:

Adrian L Harris1
1University of Oxford, Oxford, UK

Functional characterisation of new molecular mechanisms involved in epithelial lumen morphogenesis

Year:

Session type:

Fernando Martin-Belmonte1
1CSIC-UAM Centro de Biología Molecular Severo Ochoa

Application of risk prediction to breast cancer prevention

Year:

Session type:

Douglas Easton1
1University of Cambridge, Cambridge, UK

Fat cadherins in the regulation of planar polarity, tissue growth and mitochondrial activity

Year:

Session type:

Helen McNeill1
1University of Toronto and Lunenfeld-Tanenbaum Institute of Mount Sinai Hospital, Toronto, Canada

Immunotherapy of childhood cancer

Year:

Session type:

John Anderson1
1Institute of Child Health, London, UK

Cancer immunology and immunotherapy: Building on success

Year:

Session type:

Sergio Quezada1
1University College London Cancer Institute, London, UK

Late effects of childhood cancer: What are the consequences for long-term survivors and how can they be reduced?

Year:

Session type:

Melissa M Hudson1
1St Jude Children’s Research Hospital, Memphis, USA

Working together to exploit a rich seam of novel epigenetic targets for cancer

Year:

Session type:

Chas Bountra1
1University of Oxford, Oxford, UK

Molecular stratification and clinical management of adult high-grade glioma

Year:

Session type:

Colin Watts1
1University of Cambridge, Cambridge, UK

Cancer epigenetics: From mechanism to therapy

Year:

Session type:

Mark Dawson1
1Cambridge Institute for Medical Research & Wellcome Trust and Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, UK

Predictive markers for response to adjuvant procarbazine, lomustine (CCNU) and vincristine (PCV) in anaplastic oligodendrogliomas and oligoastrocytomas

Year:

Session type:

Pim French1
1Erasmus MC, Rotterdam, The Netherlands